Navigation Links
New target for medicine to combat Alzheimer's: VIB scientists confirm protein's key role
Date:2/12/2009

Alzheimer's disease

Two thirds of all patients with dementia suffer from Alzheimer's disease. Estimates indicate that by 2010 our country will have more than 150,000 Alzheimer's patients. Alzheimer's is a disease that gradually destroys brain cells, with the result that the mental capacity of patients with Alzheimer's gradually declines. At first, memory begins to fail, but the patient's cognitive capabilities also deteriorate as the disease progresses. Today, this disease cannot yet be cured. Current medicines for Alzheimer's patients sustain the memory functions for a short time, but they are unable to stop the brain cells from dying off. At best, they are able to limit the loss of memory during the early phases of the disease.

The β-amyloid cascade

The brains of Alzheimer's patients typically show the presence of amyloid plaques, which are abnormal accumulations of a protein (β-amyloid) between the neurons. The sticky β-amyloid develops when the precursor protein (amyloid precursor protein or APP) is cut into pieces incorrectly.

GPR3: target for new medicine

Several years ago, Bart De Strooper and other researchers elucidated the way in which these plaques originate and discovered that secretases play a large role in this process. Now, under the direction of Bart De Strooper, and in collaboration with researchers from the biotech company Galapagos, Amantha Thathiah and her colleagues have investigated whether additional substances are also involved in the development of the plaques. Which is apparently the case: Galapagos has identified the GPR3 protein as a new player. The VIB researchers have been able to show − in vitro (in cells isolated and studied in the laboratory) as well as in vivo (in living animals − mice, in this instance) − that blocking GPR3 leads to reduction of the plaques.

Importance of this research

The GPR3 protein is an important targe
'/>"/>

Contact: Pieter Van Dooren
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Page: 1 2

Related biology news :

1. Nicotinic receptors may be important targets for treatment of multiple addictions
2. New target for anti-flu drug development
3. Central targets may hinder wider waste management objectives
4. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
5. UIC researchers find promising new targets for antibiotics
6. Targeting nerve growth factor may cure liver cancer
7. Study by Pittsburgh researchers identifies possible vaccine target for chlamydia
8. Linchpin gene may be useful target for new breast cancer therapies
9. Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine
10. Study reveals a key to blood vessel growth and possible drug target
11. Microarray sequence capture speeds large-scale resequencing of targeted genomic regions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
(Date:11/18/2014)... Nov. 17, 2014   News ... collaborate to develop The Partners Data Lake, an ... Partners Data Lake will allow researcher and clinicians ... treatment and the lives of patients , ... clinical activities across the Partners system, breaking down ...
(Date:11/15/2014)... 2014  While we may still be a few years ... "Star Trek" to gain instant access to all that ailed ... smartphones and tablets for monitoring and measuring our health are ... may seem a tad Orwellian to some, but a new ... these technological opportunities into their healthcare regime. These ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... University of Nottingham have won a prestigious international ... Professor Liz Sockett and colleagues at Nottingham, ... University of Hiroshima, Japan, have jointly been awarded ... honour of their bacterial research. Daiwa Adrian ...
... Police Launch Multi-agency Data Interoperability System, ... (OTC Bulletin Board: BKYI), a leader in ... and its partner,DaProSystems today announced a contract ... a mobile data solution. Harrisonburg,s police,department has ...
... technology developed by a University of Colorado at Boulder ... vents has been used to identify unexpected bacteria strains ... cystic fibrosis, findings that may lead to more effective ... nucleic acid gene sequencing to rapidly detect, identify and ...
Cached Biology News:Honor for UK-Japanese research 2Wireless Public Safety Solution From BIO-key(R) and DaProSystems Links Virginia Law Enforcement Agencies 2Wireless Public Safety Solution From BIO-key(R) and DaProSystems Links Virginia Law Enforcement Agencies 3CU-Boulder technology used to identify unexpected bacteria in cystic fibrosis patients 2
(Date:11/27/2014)... Nov. 27, 2014 Research and ... "Global Palmitic Acid Industry Report 2014" report to ... The Global Palmitic Acid Industry Report 2014 ... state of the global palmitic acid industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:11/27/2014)... November 26, 2014 Biomedical devices that ... systems to enable 3D manufacture at the micro-nanoscale, and ... are among finalists in nine categories for the ... are sponsored by SPIE, the international society for ... , Winners will be announced by industry leaders on ...
(Date:11/26/2014)... November 26, 2014 The North ... segments the market for detailed analysis of the ... market to reach $616.3 million by 2018, growing ... 2018. , Browse through the TOC of the ... get an idea of the in-depth analysis and ...
(Date:11/26/2014)... , Nov. 26, 2014 The ... results from a survey of European physicians at ... on Innovation and Biological Therapies" at the Spanish ... event, hosted by EuropaBio and the Spanish Bioindustry ... of Health, physicians from Spanish oncology and rheumatology ...
Breaking Biology Technology:Global Palmitic Acid Industry Report 2014 2Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3ASBM Presents European Physicians Survey at Spanish Ministry of Health 2
... (LSE: SHP, NASDAQ: SHPGY) the global specialty,biopharmaceutical company announces results ... Q2 2008 Financial Highlights, - Product sales up ... up 64% to $409m - New product sales(1) $243m, ... up 35% to $776m - US GAAP earnings per ...
... Neuropharmaceuticals,Inc., a formulator of pharmaceuticals for direct-to-the-brain ... capital Series A,financing. Co-leads in the funding ... Partners. Other investors include High Country,Venture and ... proprietary drug development process that makes use ...
... 32% Over Second Quarter 2007, - EPS of $0.63 per Basic Share, ... Charges of $1.36 per Basic Share, Increase of ... 56% Over Second Quarter 2007, SILVER ... announced its results of,operations for the quarter ended June 30, 2008., ...
Cached Biology Technology:Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 2Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 3Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 4Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 5Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 6Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 7Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 8Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 9Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 10Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 11Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 12Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 13Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 14Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 15Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 16Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 17Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 18Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 19Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 20Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 21Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 22Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 23Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 24Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 25Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 26Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 27Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 28Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 29Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 30Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 31Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 32Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 33Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round 2Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round 3United Therapeutics Reports Second Quarter 2008 Financial Results 2
... in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and ... royalties for your hard work and endeavour! ... build it up,and market it internationally. We ...
Topoisomerase I...
...
... virus is a type I eukaryotic topoisomerase ... turns (also called right- and left-handed supercoils) ... the reaction is a covalently closed, circular ... turns. DNA Topoisomerase I does not absolutely ...
Biology Products: